DUNN JEFFREY W sold $369K of SIBN

DUNN JEFFREY W sold 20,000 shares of SI-BONE, Inc. (SIBN) at $18.46 ($0.37M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DUNN JEFFREY W
Published Aug 5, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The disclosed fact is the size, price, and timing of the director’s open-market sale, plus confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 framing reduces the likelihood of a fundamental signal.

03

What to watch

The article does not state whether there were concurrent purchases, option exercises, or other insider activity around the same period, which could change interpretation.

Relevance 3/10Novelty 3/10Timing: Form 4 filed Aug 5, covering an Aug 3 sale.

Background

The article is a SEC Form 4 insider transaction disclosure for SI-BONE, Inc., reported by a director.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

SI-BONE director Jeffrey W Dunn sold 20,000 shares in an open-market transaction on Aug 3 at $18.4607, per Form 4 filed Aug 5.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a routine Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed in the text.

Market effects

No sector-level implications are provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • SI-BONE, Inc.

    Company whose director insider sale is disclosed in the Form 4.

  • DUNN JEFFREY W

    Director who sold 20,000 shares on Aug 3 under an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.